Literature DB >> 17350750

Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.

Alberto Briganti1, Felix K-H Chun, Georg C Hutterer, Andrea Gallina, Shahrokh F Shariat, Andrea Salonia, Vincenzo Scattoni, Luc Valiquette, Francesco Montorsi, Patrizio Rigatti, Markus Graefen, Hartwig Huland, Pierre I Karakiewicz.   

Abstract

OBJECTIVES: We hypothesized that the number and/or percentage of positive cores, proxies of tumor volume, could improve the ability to predict pathologic stages and/or biochemical recurrence (BCR). To test this hypothesis, we examined radical retropubic prostatectomy (RRP) data from three centers on two continents.
MATERIAL AND METHODS: Clinical data from men undergoing RRP at three different institutions were used to predict pathologic stages and BCR. Univariable and multivariable logistic analyses and Cox regression analyses were used. Predictive accuracy (PA) was assessed with the area under the receiver operating characteristics curve estimates, which were subjected to 200 bootstraps to reduce overfit bias. The statistical significance of PA gains was assessed with the Mantel-Haenszel test.
RESULTS: The number and the percentage of positive cores were independent predictors of virtually all pathologic stage outcomes and of BCR. In PA analyses, the percentage of positive cores improved the PA of pathologic stage predictions and of BCR predictions between 0.06% and 1.49%. Conversely, the number of positive cores improved the PA of pathologic stage predictions and of BCR predictions between 0.36% and 1.14%.
CONCLUSIONS: The information derived from biopsy cores is important and can improve the ability to predict pathologic stage and BCR. It appears that the percentage of cores is most helpful in stage predictions. Conversely, the number of cores appears to improve mostly BCR predictions. Consideration of both variables might not be helpful because of the similarity of information they encode. European Association of Urology

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350750     DOI: 10.1016/j.eururo.2007.02.054

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

1.  Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

Authors:  Andrea Salonia; Andrea Gallina; Firas Abdollah; Alberto Briganti; Umberto Capitanio; Nazareno Suardi; Matteo Ferrari; Marco Raber; Renzo Colombo; Massimo Freschi; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2011-09-21       Impact factor: 4.226

2.  Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

Authors:  Minoru Kobayashi; Akinori Nukui; Kazumi Suzuki; Shinsuke Kurokawa; Tatsuo Morita
Journal:  Int J Clin Oncol       Date:  2011-04-23       Impact factor: 3.402

3.  Various morphometric measurements of cancer extent on needle prostatic biopsies: which is predictive of pathologic stage and biochemical recurrence following radical prostatectomy?

Authors:  Maisa M Q Quintal; Luciana R Meirelles; Leandro L L Freitas; Luis A Magna; Ubirajara Ferreira; Athanase Billis
Journal:  Int Urol Nephrol       Date:  2011-02-22       Impact factor: 2.370

4.  Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study.

Authors:  Nobumichi Tanaka; Kiyohide Fujimoto; Akihide Hirayama; Kazumasa Torimoto; Eijiro Okajima; Masahiro Tanaka; Makito Miyake; Keiji Shimada; Noboru Konishi; Yoshihiko Hirao
Journal:  Int J Clin Oncol       Date:  2011-03-25       Impact factor: 3.402

5.  Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Tim Oliver; Henrik Møller; Victor Reuter; Peter Scardino; Jack Cuzick; Daniel M Berney
Journal:  Virchows Arch       Date:  2010-09-09       Impact factor: 4.064

6.  Radiation treatment for patients with intermediate-risk prostate cancer.

Authors:  David E Greene; Jyoti S Mayadev; Richard K Valicenti
Journal:  Ther Adv Urol       Date:  2012-06

7.  Calculated tumor volume is an independent predictor of biochemical recurrence in patients who underwent retropubic radical prostatectomy.

Authors:  Nobumichi Tanaka; Kiyohide Fujimoto; Akihide Hirayama; Yasushi Nakai; Yoshitomo Chihara; Satoshi Anai; Atsushi Tomioka; Keiji Shimada; Noboru Konishi; Yoshihiko Hirao
Journal:  Adv Urol       Date:  2012-05-13

8.  Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.

Authors:  Masahiro Yashi; Akinori Nukui; Yuumi Tokura; Kohei Takei; Issei Suzuki; Kazumasa Sakamoto; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Hideyuki Abe; Yoshitatsu Fukabori; Yoshimasa Nakazato; Yasushi Kaji; Takao Kamai
Journal:  BMC Urol       Date:  2017-06-23       Impact factor: 2.264

9.  Low levels of serum testosterone in middle-aged men impact pathological features of prostate cancer.

Authors:  Elton Llukani; Benjamin F Katz; Ilir Agalliu; Andrew Lightfoot; Sue-Jean S Yu; Martin Kathrins; Ziho Lee; Yu-Kai Su; Kelly Monahan Agnew; Alice McGill; Daniel D Eun; David I Lee
Journal:  Prostate Int       Date:  2017-01-12

10.  Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years.

Authors:  Weigang Yan; Jian Chen; Yi Zhou; Zhien Zhou; Zhipeng Mai; Zhigang Ji; Hanzhong Li; Fuquan Zhang
Journal:  Springerplus       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.